Testing GFH276 with cetuximab or chemo for RAS-mutated cancers
Part of Cancer clinical trials.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a cancer (solid tumor or pancreatic cancer) that has spread or can't be removed with surgery and has a RAS mutation or KRAS amplification.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of more than 3 months.
- You must have normal organ function and be willing to use effective birth control if you can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
This trial tests a new drug called GFH276 for people with advanced solid tumors that have a RAS mutation. It aims to see if the drug is safe and effective against these tumors.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.